<?xml version="1.0" encoding="UTF-8"?>
<abstract abstract-type="teaser">
 <p>In this issue of 
  <italic>Blood</italic>, 
  <related-article related-article-type="article-reference" id="d38e95" ext-link-type="doi" xlink:href="10.1182/blood.2020006964" xmlns:xlink="http://www.w3.org/1999/xlink">Hegerova et al</related-article> report on a study of 20 hospitalized patients with severe or critical coronavirus disease 2019 (COVID-19) who were transfused with convalescent plasma (CP); the authors suggest a favorable, albeit modest, benefit as compared with 20 matched (ie, nontransfused) controls, particularly when transfusion was undertaken within the first 7 days of hospitalization.
  <sup>
   <xref rid="B1" ref-type="bibr">1</xref>
  </sup>
 </p>
</abstract>
